Association between overexpression of Wip1 and prognosis of patients with non-small cell lung cancer

Zhao,Min; Zhang,Hongbin; Zhu,Guiyun; Liang,Jian; Chen,Ning; Yang,Yonghui; Liang,Xiangcun; Cai,Hongmei; Liu,Wei

doi:10.3892/ol.2016.4245

Association between overexpression of Wip1 and prognosis of patients with non-small cell lung cancer

Authors:
- Min Zhao
- Hongbin Zhang
- Guiyun Zhu
- Jian Liang
- Ning Chen
- Yonghui Yang
- Xiangcun Liang
- Hongmei Cai
- Wei Liu
View Affiliations

Affiliations: Department of Oncology, Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Lung Oncology, Hebei Chest Hospital, Research Center of Hebei Lung Cancer Prevention and Treatment, Shijiazhuang, Hebei 050041, P.R. China, Department of Pathology, Hebei Chest Hospital, Research Center of Hebei Lung Cancer Prevention and Treatment, Shijiazhuang, Hebei 050041, P.R. China
Published online on: February 18, 2016 https://doi.org/10.3892/ol.2016.4245
Pages: 2365-2370
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wild-type p53-induced phosphatase 1 (Wip1), also termed PPM1D, is a member of the protein phosphatase 2C family, which is characterized by distinctive oncogenic properties. Overexpression of Wip1 is observed in certain types of human tumors that are associated with significantly poor prognosis. The present study aimed to detect the expression of Wip1 in non‑small cell lung cancer (NSCLC) and to analyze its prognostic value in such patients. The protein expression level of Wip1 was compared between NSCLC and normal lung tissue specimens using by immunohistochemistry, and it was found that Wip1 was highly expressed in NSCLCs but was absent or weakly expressed in normal lung tissues. Detailed clinical and demographic information of patients were retrospectively collected pre‑ and postoperatively, and Kaplan‑Meier survival and Cox's regression analyses were performed to evaluate the prognosis of patients. Survival analysis revealed that the overall survival rate for patients in the Wip1‑positive expression group was significantly lower than that of the Wip1‑negative group, and Cox multivariate analysis indicated that positive Wip1 expression, pN classification and pathological stage were significant prognostic predictors. The results of the current study suggest that Wip1 may be associated with pathological diagnosis and prognostic evaluation of NSCLC.

View Figures

View References

1	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
2	Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL and Piccirillo J: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 24:4539–4544. 2006. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
4	Sun S, Schiller JH, Spinola M and Minna JD: New molecularly targeted therapies for lung cancer. J Clin Invest. 117:2740–2750. 2007. View Article : Google Scholar : PubMed/NCBI
5	Ciancio N, Galasso MG, Campisi R, Bivona L, Migliore M and Di Maria GU: Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med. 7:292012. View Article : Google Scholar : PubMed/NCBI
6	Moorhead GB, Trinkle-Mulcahy L and Ulke-Lemée A: Emerging roles of nuclear protein phosphatases. Nat Rev Mol Cell Biol. 8:234–244. 2007. View Article : Google Scholar : PubMed/NCBI
7	Fiscella K, Franks P and Shields CG: Perceived family criticism and primary care utilization: Psychosocial and biomedical pathways. Fam Process. 36:25–41. 1997. View Article : Google Scholar : PubMed/NCBI
8	Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M and Donehower LA: The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27:123–135. 2008. View Article : Google Scholar : PubMed/NCBI
9	Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, et al: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 434:907–913. 2005. View Article : Google Scholar : PubMed/NCBI
10	Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA and Kim JY: Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 86:245–256. 2008. View Article : Google Scholar : PubMed/NCBI
11	Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T and Inazawa J: PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 63:1876–1883. 2003.PubMed/NCBI
12	Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J and Imoto I: Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res. 9:1995–2004. 2003.PubMed/NCBI
13	Hu W, Feng Z, Modica I, Klimstra DS, Song L, Allen PJ, Brennan MF, Levine AJ and Tang LH: Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer. 1:360–368. 2010. View Article : Google Scholar : PubMed/NCBI
14	Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, et al: Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet. 31:133–134. 2002. View Article : Google Scholar : PubMed/NCBI
15	Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J and Hayashi Y: Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci. 102:1101–1106. 2011. View Article : Google Scholar : PubMed/NCBI
16	Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC: Tumours of the lung. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press. (Lyon). 102004.
17	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L: International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
18	Park JY, Song JY, Kim HM, Han HS, Seol HS, Jang SJ and Choi J: p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors. Int J Biochem Cell Biol. 44:896–904. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, et al: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 31:210–215. 2002. View Article : Google Scholar : PubMed/NCBI
20	Nannenga B, Lu X, Dumble M, Van Maanen M, Nguyen TA, Sutton R, Kumar TR and Donehower LA: Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog. 45:594–604. 2006. View Article : Google Scholar : PubMed/NCBI
21	Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E and Bulavin DV: The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene. 26:2502–2506. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zhao JX, ZW, Sun L, Luo HH and Gu Y: Expression of Wip1 in non small cell lung cancer tissue and cells. Chin J Pathophysiol. 25:1731–1735. 2009.(In Chinese).
23	Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR and Albelda SM: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. Clin Cancer Res. 11:3974–3986. 2005. View Article : Google Scholar : PubMed/NCBI
24	Hirasawa A, Aoki D, Inoue J, Imoto I, Susumu N, Sugano K, Nozawa S and Inazawa J: Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res. 9:5675–5682. 2003.PubMed/NCBI
25	Liang C, Guo E, Lu S, Wang S, Kang C, Chang L, Liu L, Zhang G, Wu Z, Zhao Z, et al: Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas. Brain Res. 1444:65–75. 2012. View Article : Google Scholar : PubMed/NCBI
26	Campling BG and El-Deiry WS: Clinical implication of p53 mutation in lung cancer. Mol Biotechnol. 24:141–156. 2003. View Article : Google Scholar : PubMed/NCBI